Silexion Therapeutics Files 8-K on Warrants
Ticker: SLXNW · Form: 8-K · Filed: Jan 28, 2025 · CIK: 2022416
Sentiment: neutral
Topics: warrants, disclosure, corporate-action
Related Tickers: SLXN
TL;DR
Silexion Therapeutics filed an 8-K regarding warrants exercisable at $11.50.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) announced on January 28, 2025, that it has filed a Form 8-K. The company, incorporated in the Cayman Islands and operating in the Biological Products sector, is headquartered in Ramat-Gan, Israel. This filing is related to warrants exercisable for ordinary shares at an exercise price of $11.50 per share.
Why It Matters
This filing provides an update on the company's financial instruments, specifically warrants, which could impact future share structure and dilution.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of warrants and does not indicate immediate financial distress or significant operational changes.
Key Numbers
- $11.50 — Warrant Exercise Price (This is the price at which holders can exercise their warrants to purchase ordinary shares.)
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- January 28, 2025 (date) — Date of report
- Cayman Islands (jurisdiction) — State of incorporation
- Ramat-Gan, Israel (location) — Principal executive offices
- $11.50 (dollar_amount) — Exercise price of warrants
FAQ
What is the total number of warrants outstanding?
The filing does not specify the total number of warrants outstanding.
When do these warrants expire?
The filing does not mention the expiration date of the warrants.
What is the purpose of this 8-K filing?
The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, related to warrants exercisable for ordinary shares.
Has Silexion Therapeutics Corp. undergone a name change recently?
Yes, the company was formerly known as Biomotion Sciences, with a date of name change on May 6, 2024.
What is the ticker symbol for Silexion Therapeutics Corp?
The filing mentions 'slxn' in relation to warrants and shares, suggesting it is the ticker symbol.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-01-28 08:56:39
Key Financial Figures
- $0.0009 — registered Ordinary Shares, par value $0.0009 per share SLXN The Nasdaq Stock Mar
- $103.50 — Ordinary Shares at an exercise price of $103.50 per share SLXNW The Nasdaq Stock Ma
Filing Documents
- zk2532610.htm (8-K) — 49KB
- exhibit_99-1.htm (EX-99.1) — 15KB
- image00003.jpg (GRAPHIC) — 23KB
- 0001178913-25-000247.txt ( ) — 280KB
- slxn-20250128.xsd (EX-101.SCH) — 5KB
- slxn-20250128_def.xml (EX-101.DEF) — 18KB
- slxn-20250128_lab.xml (EX-101.LAB) — 27KB
- slxn-20250128_pre.xml (EX-101.PRE) — 20KB
- zk2532610_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 28, 2025, Silexion Therapeutics Corp issued a press release entitled "Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models." A copy of the press release is furnished with this Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated January 28, 2025 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: January 28, 2025 /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer